血液透析的甲状腺癌患者接受放射性碘治疗的管理:里尔经验
该单中心回顾性研究纳入16例因终末期肾病接受血液透析的甲状腺癌患者,评估放射性碘治疗的肿瘤学结果与毒性风险,并比较三种骨髓吸收剂量估算模型。中位放射性碘活度为2913 MBq,耐受性良好,骨髓吸收剂量在不同模型间存在统计学差异;未发现总血放射性活度下降与总净化血容量显著相关,无患者在给予3700 MBq时超过2 Gy阈值。作者建议常规减少放射性碘活度可能过于谨慎。
要点
- 中位放射性碘活度2913 MBq时即时和晚期耐受性良好。
- 三种模型估算的中位骨髓吸收剂量分别为0.72、0.81和0.67 Gy,差异有统计学意义。
- 给予3700 MBq时无患者骨髓吸收剂量超过2 Gy阈值。
核心结论
- 在血液透析的甲状腺癌患者中,按该中心透析方案,常规减少放射性碘活度可能过于谨慎且不必要。
研究设计与样本
- 单中心回顾性研究,纳入所有因甲状腺癌需要放射性碘治疗的血液透析终末期肾病患者,共16例。
主要发现
- 中位放射性碘活度为2913 MBq,即时和晚期耐受性良好。
- 模型1、2、3估算的中位骨髓吸收剂量分别为0.72、0.81和0.67 Gy,所有计算方法间差异有统计学意义。
- 总血放射性活度下降与总净化血容量之间无显著相关性。
- 给予3700 MBq活度时无患者超过2 Gy阈值。
关键数值与推荐
- 每次透析净化血容量65-70 L目标下,两次透析后放射性活度降低超过90%。
- 骨髓吸收剂量2 Gy阈值:给予3700 MBq时无患者超过该阈值。
临床怎么用
- 对于血液透析的甲状腺癌患者,采用该中心透析方案时可不常规减少放射性碘活度。
- 可参考每次透析净化血容量65-70 L的目标以实现两次透析后放射性活度降低超过90%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of radioactive iodine (RAI) for patients with thyroid cancer (TC) who are also treated with hemodialysis for end-stage renal disease (HD-ESRD) remains challenging, with several issues still unresolved. We report our tertiary referral center experience and provide suggestions for management improvement. Methods: We included all HD-ESRD patients that required RAI for TC in our institution. Oncologic results and toxicity risk were evaluated. Blood marrow (BM) absorbed dose was estimated on the basis of current guidelines and compared with 2 alternative models that adapt to the inability of using biexponential models for hemodialyzed patients. We emulated the impact of high RAI activity on the BM absorbed dose. Dialysis parameters were reviewed to correlate with kinetics of RAI activity. The impact of 2 different schema of recombinant human thyrotropin stimulating hormone was also studied. Results: In total, 16 patients were included. Fifteen patients were prepared with recombinant human thyrotropin stimulating hormone (5 with 1 injection on day 2, 10 with 2 injections on days 10 and 2). Median RAI activity was 2913 MBq, and immediate and late tolerance was good. The median BM absorbed dose was 0.72, 0.81, and 0.67 Gy with models 1, 2, and 3, respectively, statistically different among all calculation methods. There was no significant correlation between total blood activity decrease and total purified blood volume. No patient crossed the 2-Gy threshold with a delivered activity of 3700 MBq. Conclusion: On the basis of the largest series of HD-ESRD patients treated with RAI for TC, we present findings that could enhance their management. With our hemodialysis protocol, we suggest that routine reductions in RAI activity may be overly cautious and unnecessary. Oncologic outcomes were favorable, without significant hematologic toxicity. A 65-70 L of purified blood volume per session target results in over 90% reduction in radioactivity after 2 dialysis sessions.
引用
- Chevalier B, Devos L, Baillet C, et al. Management of Hemodialyzed Patients Treated with Radioactive Iodine for Thyroid Cancer: How Could We Improve It? Tracks from the Lille Experience. J Nucl Med. 2026. PMID: 42134980. doi:10.2967/jnumed.125.271707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。